Aggen et al. conducted a study using a renal carcinoma (RENCA) cell line model of renal cancer and observed that the combination of anti-IL-1β and PD-1 inhibitors effectively enhanced anti-tumor activity. Here, PDCD1 is linked to renal carcinoma.